TCT-15 Results of the Primary Endpoint of the PLATINUM PLUS Trial: A Prospective, Randomized, Multi-center Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization in a Population of Unrestricted Patients

Jean Fajadet,Eulogio J Garcia,David Hildick-Smith,Franz-Josef Neumann,Anna Sonia Petronio,Mark S Spence,Jochen Wöhrle,Azfar Zaman,Simon Elhadad,Sigmund Silber

doi:10.1016/j.jacc.2013.08.743

TCT-15 Results of the Primary Endpoint of the PLATINUM PLUS Trial: A Prospective, Randomized, Multi-center Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization in a Population of Unrestricted Patients

Jean Fajadet, Eulogio J Garcia + Show 8 more

Open Access

https://doi.org/10.1016/j.jacc.2013.08.743

Copy DOI

Journal: Journal of the American College of Cardiology	Publication Date: Oct 1, 2013
License type: publisher-specific-oa

Affiliation: Clinique Pasteur, Royal Sussex County Hospital, Universitäts-Herzzentrum Freiburg-Bad Krozingen, University of Pisa, Royal Victoria Hospital, University of Ulster, University Hospital Ulm, Freeman Hospital, Rechts der Isar Hospital

#PLATINUM PLUS #PLUS Trial + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

A drug-eluting stent consists of 3 components of equal importance: a metallic platform, a polymer and a drug, all influencing acute and long term results both in safety and efficacy. The PLATINUM PLUS trial was designed to compare the PROMUS Element(tm) stent (Boston Scientific; Natick, MA, US) to

Full Text